Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on May 28, 2021 9:33am
148 Views
Post# 33285019

RE:RE:RE:RE:GWX - SPDR(R) S&P(R)International Small Cap ETF

RE:RE:RE:RE:GWX - SPDR(R) S&P(R)International Small Cap ETF I wouldn't disagree and I think they plan on doing that.  Ultimately we need the scientific data to push the pipeline forward. I just think given the situation they're in with a very limited following and inability to break through with news that they'll need the hard facts to convince others to look at it --hopefully positive hard facts.

One thing I hope they will do once oncology is further along (and eventually with NASH at the mid-phase data check) is to lay out a very general 3 and 5 year strategic plan with broad ranges for key financial targets. Many companies do that once they've established some element of predictability of commercialization. I'm not talking anything out-of-the-normal. But you should be able to say post cancer Phase 2 data that you foresee usage initially in these types of tumors and these lines of treatment, and expect early penetration rates of X, growing to Y and that would represent revenue ranges of A to B.  Then moving down to 2L, 3L could add C.  THen trialing for Mylenoma's, etc...  They've got to put a financial picture around the future once they have a higher confidence in any of the pipeline commercialization.  I see this kind of strategic target plans in many of the biotechs once they've heavily de-risked a drug for an indication. 

That would help immensely. 

scarlet1967 wrote:
That’s one way to see it but I would rather see increasing volume and valuation on a steady basis in line with company’s progresses instead of a single big bang effect as a result of announcing all the potential good news at once. Constant big or small news flow keeps the story relevant rather than big one off announcements which can fade away as some trader would move on to come back later when they anticipate the next big announcement is about to happen.
For me the ideal strategy(in that order or different one based on their progress in various projects) would  be going forward have the life science report produced once the harmonized NASH protocol is finalized and present it to the market more than once followed by later on hopefully good cancer results followed by dosing of first patient for NASH phase 3 followed by launch of Trogarzo IV push followed by commercialization of Trogarzo in the Europe followed by launch of F8 followed by phase 2 cancer followed by lunch of Trogarzo IM  etc. etc. So the news flow is frequent and constant to keep the investors excited. The company should create the narratives for investors to stay inversed rather than in and out trading of the stock, the company needs to get the attention of  investors rather than trader now more than ever as they potentially have the ammunition(a cascade of potential encouraging achievements both in the R&D and commercial sides). 
 

Lee430 wrote: Hanging my hopes on Winos theory that this low volume might initialy help us if good news breaks out, after Memorial day maybe when traders are back at the WFH desk.

Bucknelly21 wrote: Another 20k share day ...

 




<< Previous
Bullboard Posts
Next >>